Penicilliosis

Summary

Penicilliosis (MONDO:0000304) is a disease and 1 clinical trial. A subtype of opportunistic systemic mycosis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 1

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	penicilliosis
Mondo ID	MONDO:0000304
Orphanet	697053
DOID	DOID:0050288
ICD-11	646368820
SNOMED CT	372936000, 713315007
UMLS	C1274008
MedGen	697372
Is cancer (heuristic)	no

Also known as: infection caused by Penicillium marneffei · infection caused by Talaromyces marneffei · infection due to Penicillium marneffei · Penicillium marneffei infectious disease · Talaromyces marneffei caused disease or disorder · Talaromyces marneffei disease or disorder · Talaromyces marneffei infectious disease

Disease family

Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › fungal infectious disease › systemic mycosis › opportunistic systemic mycosis › penicilliosis

Related subtypes (2): trichosporonosis, disseminated candidiasis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 1.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04031053	Not specified	UNKNOWN	Itraconazole Pharmacokinetic With and Without Efavirenz Using the Capsule Formulation as Part of Talaromycosis Treatment in HIV-infected Adults